These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6424978)

  • 21. Bromocriptine response in normoprolactinemic patients with polycystic ovary disease: a preliminary report.
    Seibel MM; Oskowitz S; Kamrava M; Taymor ML
    Obstet Gynecol; 1984 Aug; 64(2):213-9. PubMed ID: 6234484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypogonadism, galactorrhoea and hyper-prolactinaemia: Evaluation of pituitary gonadotrophins reserve before and under bromocriptine.
    Asfour M; L'Hermite M; Hedouin-Quincampoix M; Fossati P
    Acta Endocrinol (Copenh); 1977 Apr; 84(4):738-49. PubMed ID: 322432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The hormonal response of patients with polycystic ovarian disease to subcutaneous low frequency pulsatile administration of luteinizing hormone-releasing hormone.
    Hurwitz A; Rosenn B; Palti Z; Ebstein B; Har-Nir R; Ron M
    Fertil Steril; 1986 Sep; 46(3):378-84. PubMed ID: 2943606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The utility of the gonadotrophin releasing hormone (GnRH) test in the diagnosis of polycystic ovary syndrome (PCOS).
    Lewandowski KC; Cajdler-Łuba A; Salata I; Bieńkiewicz M; Lewiński A
    Endokrynol Pol; 2011; 62(2):120-8. PubMed ID: 21528473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ovarian morphology as a predictor of hormonal values in polycystic ovary syndrome.
    van der Westhuizen S; van der Spuy ZM
    Ultrasound Obstet Gynecol; 1996 May; 7(5):335-41. PubMed ID: 8774098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycycstic ovary disease after discontinuation of treatment.
    Genazzani AD; Battaglia C; Gamba O; Petraglia F; Malavasi B; Genazzani AR
    J Assist Reprod Genet; 2000 May; 17(5):269-75. PubMed ID: 10976414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
    J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol.
    Laganà AS; Barbaro L; Pizzo A
    Arch Gynecol Obstet; 2015 May; 291(5):1181-6. PubMed ID: 25416201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
    Song J; Shen H; Li J; Huang Z; Zhang Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endocrine changes after laparoscopic ovarian drilling in clomiphene citrate-resistant women with polycystic ovarian syndrome.
    Al-Ojaimi EH
    Saudi Med J; 2004 Aug; 25(8):1032-9. PubMed ID: 15322594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of ovarian wedge resection for the Stein-Leventhal syndrome on plasma FSH, LH, oestradiol and testosterone levels and on the responses of the pituitary to intravenous LHRH.
    Valkov IM; Dokumov SI
    Br J Obstet Gynaecol; 1977 Jul; 84(7):539-42. PubMed ID: 334239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome.
    Adams JM; Taylor AE; Crowley WF; Hall JE
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4343-50. PubMed ID: 15356031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients.
    Balen AH; Conway GS; Kaltsas G; Techatrasak K; Manning PJ; West C; Jacobs HS
    Hum Reprod; 1995 Aug; 10(8):2107-11. PubMed ID: 8567849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperprolactinaemia in polycystic ovary syndrome.
    Lunde O
    Ann Chir Gynaecol; 1981; 70(4):197-201. PubMed ID: 6797343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
    Ruchhoft EA; Elkind-Hirsch KE; Malinak R
    Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of the antiserotoninergic preparation cyproheptadine on the levels of luteinizing and follicle-stimulating hormones and testosterone in patients with polycystic ovaries].
    Tudose TI
    Probl Endokrinol (Mosk); 1987; 33(3):22-5. PubMed ID: 3116528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The therapeutic effect of parlodel in the polycystic ovary syndrome].
    Soboleva EL; Komarov EK; Potin VV; Svechnikova FA
    Akush Ginekol (Mosk); 1990 Sep; (9):61-3. PubMed ID: 2278313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.